Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Johnson & Johnson (JNJ) Shares Advance +10.6% Over 30 Days on Solid Pipeline Momentum

Johnson & Johnson (JNJ) Shares Advance +10.6% Over 30 Days on Solid Pipeline Momentum

Key Takeaways

  • Johnson & Johnson (JNJ) shares advanced roughly 10.6% over the trailing 30 days, climbing from about $255.56 to near $282.77.
  • The move followed better-than-expected third-quarter results, a raised full-year 2026 outlook, and continued momentum in oncology and immunology.
  • FDA accelerated approval of RYBREVANT FASPRO for advanced head and neck cancer reinforced confidence in the company's pipeline.
  • Over the trailing quarter, the stock is up about 7.8%, extending a longer climb that has carried shares to all-time highs.
  • Strong Innovative Medicine growth helped offset a softer MedTech quarter and a large one-time talc-related charge.

Johnson & Johnson Company Overview and Market Position

Johnson & Johnson (JNJ) remains one of the world's largest and most diversified healthcare companies, operating through its Innovative Medicine and MedTech segments. The Innovative Medicine side focuses on pharmaceuticals in oncology, immunology, neuroscience, cardiovascular, and pulmonary hypertension, with key products like DARZALEX, TREMFYA, and CARVYKTI. MedTech covers surgical technologies, orthopaedics, cardiovascular devices, and vision care. I follow the stock for its reliable cash flows, long history of dividend increases, and efforts to lead in oncology while expanding into areas like robotic surgery.

Johnson & Johnson Stock Price Performance Over the Last 30 Days and Quarter

Over the trailing 30 days, JNJ shares rose approximately 10.6%, moving from a close near $255.56 to about $282.77 at the latest available price. The path included some consolidation in mid-October before a stronger push in late October and November, reaching a record high near $282.03 in early November. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Over the broader trailing quarter, the stock gained roughly 7.8% from its mid-August level near $262.37. This advance reflects an improving growth story in pharmaceuticals, even with softer MedTech results and the one-time legal charge in the third-quarter report.

What Supported the Recent 30-Day Advance

Several clear catalysts backed the move. In mid-October, Johnson & Johnson reported third-quarter worldwide sales of $25.4 billion, up about 5.9% year over year, with adjusted diluted EPS of $2.59. Management raised full-year 2026 guidance, with the midpoint of reported sales lifted to roughly $101.2 billion and adjusted diluted EPS to about $11.10. Investors focused on operational strength in oncology and immunology rather than the GAAP impact from the proposed talc litigation resolution.

In early November, the FDA granted accelerated approval to RYBREVANT FASPRO for adults with recurrent or metastatic head and neck squamous cell carcinoma, based on a 42% confirmed overall response rate in the OrigAMI-4 trial. This expanded the oncology franchise and supported higher trading volume along with the push to record highs. A quarterly dividend of $1.34 per share and broader interest in defensive healthcare names also helped sentiment.

Drivers Behind the Quarterly Performance

The quarterly trend ties into a broader portfolio shift. Innovative Medicine delivered operational sales growth of 7.9% in the third quarter, driven by double-digit gains in oncology assets such as DARZALEX, CARVYKTI, and TECVAYLI, plus immunology and neuroscience products like TREMFYA and CAPLYTA. Newer launches, including ICOTYDE for psoriasis and INLEXZO for bladder cancer, added to the pipeline narrative.

These positives helped offset a MedTech segment that grew only 2.5% operationally and missed internal targets, with softness mainly in international markets and the Abiomed business. Regulatory progress, including FDA De Novo authorization for the OTTAVA robotic surgery system, supports the longer-term story behind the stock's climb.

Key Areas to Watch Going Forward

Investors will monitor whether Innovative Medicine can maintain above-market growth as newer products help offset the loss of exclusivity on STELARA. MedTech recovery, especially in Abiomed and international surgery, remains a variable, along with the OTTAVA launch. Additional items include updates on the talc litigation resolution, the planned orthopaedics separation, and any 2027 guidance at the December Enterprise Business Review. Broader factors like U.S. drug-pricing reform also matter for the sector.

Exploring Tickeron AI Tools for Market Insights

In my own research process, I occasionally turn to Tickeron’s AI Trading Bots to review automated strategies that align with names like JNJ. These tools scan thousands of tickers and highlight approaches with different timeframes and performance metrics, offering a data-driven way to complement fundamental analysis without replacing it.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: JNJ

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


JNJ in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026

The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 42 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 50%.

The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 25 of 47 cases over the following month. The odds of a continued upward trend are 53%.

JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 165 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.

The Aroon Indicator entered an Uptrend today. In 124 of 260 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 48%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.

JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -3%. For the same Industry, the average monthly price growth was -0%, and the average quarterly price growth was 4%. MIRA experienced the highest price growth at 2%, while SCLX experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 32
Price Growth Rating: 40
SMR Rating: 59
Profit Risk Rating: 58
Seasonality Score: 25 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an investment holding company with interests in health care products

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
One Johnson & Johnson Plaza
Phone
+1 732 524-0400
Employees
138200
Web
https://www.jnj.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.